Cited by 177Lipoproteins and Cardiovascular HealthNitric Oxide and Endothelin EffectsCoronary Interventions and Diagnostics

The DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index.

Rapid Effect of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibition on Coronary Endothelial Function

Open access

Wassmann, Sven, Faul, Anna, Hennen, Benno, Scheller, Bruno, Böhm, Michael, Nickenig, Georg·2003·Circulation Research

DOI 10.1161/01.res.0000099503.13312.7b

Open this paper in CoChat — free account Open PDF

Abstract

Treatment with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) decreases cardiovascular event rates in hypercholesterolemic patients. Whether statins exert effects within 24 hours on the coronary vasculature in patients with endothelial dysfunction has not been elucidated. Twenty-seven patients with stable angina pectoris and average low-density lipoprotein cholesterol concentrations of 138±9 mg/dL at baseline were allocated to treatment with placebo (14 patients) or 40 mg/d pravastatin (13 patients) in a randomized, double-blind, prospective trial. Coronary endothelial function was assessed before and 24 hours after single treatment by quantitative coronary angiography during intracoronary infusion of nitroglycerin or increasing concentrations of acetylcholine (0.01, 0.1, and 1 μmol/L). Coronary blood flow reserve was measured by Doppler velocimetry during adenosine infusion. Intracoronary acetylcholine infusion induced abnormal vasoconstriction in both groups before treatment, indicating coronary endothelial dysfunction. Treatment with a single oral 40-mg dose of pravastatin significantly attenuated acetylcholine-mediated vasoconstriction after 24 hours (mean±SE decrease in luminal diameter before and after treatment: 0.01 μmol/L, 6.1±2.2% versus 3.0±1.2%; 0.1 μmol/L, 15.6±2.6% versus 7.4±1.8%; P <0.05; 1 μmol/L, 22.9±2.9% versus 13.2±2.6%; P <0.05). There was no significant difference in the response to acetylcholine in the placebo group (8.1±2.4% versus 9.7±2.4%, 16.1±2.9% versus 16.8±3.2%, and 21.4±3.9% versus 23.3±4.2%). The response to nitroglycerin infusion was not altered in both groups. Increase in coronary blood flow in response to adenosine and coronary flow reserve remained unchanged during placebo and statin treatment. Serum concentrations of blood lipids and high-sensitive C-reactive protein were not significantly altered after 24 hours in response to placebo or pravastatin therapy. Statin treatment improves endothelium-dependent coronary vasomotion within 24 hours in the absence of significant cholesterol reduction. The full text of this article is available online at http://www.circresaha.org.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1161/01.res.0000099503.13312.7b

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Atherosclerosis--an inflammatory disease
Ross, R. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901143400207 · Cited by 21,725
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial
(2002) · The Lancet · doi:10.1016/s0140-6736(02)09327-3 · Cited by 6,992
Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial
Sever, P., Dahlöf, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M. J., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12948-0 · Cited by 3,790
Prognostic Impact of Coronary Vasodilator Dysfunction on Adverse Long-Term Outcome of Coronary Heart Disease
Schächinger, V., Britten, M. B., & Zeiher, A. M. (2000) · Circulation · doi:10.1161/01.cir.101.16.1899 · Cited by 2,589
Effects of Atorvastatin on Early Recurrent Ischemic Events in Acute Coronary Syndromes<SUBTITLE>The MIRACL Study: A Randomized Controlled Trial</SUBTITLE>
Schwartz, G. G. (2001) · JAMA · doi:10.1001/jama.285.13.1711 · Cited by 2,499
Long-Term Follow-Up of Patients With Mild Coronary Artery Disease and Endothelial Dysfunction
Suwaidi, J. M. S. A., Hamasaki, S., Higano, S. T., Nishimura, R. A., Holmes, D. R., & Lerman, A. (2000) · Circulation · doi:10.1161/01.cir.101.9.948 · Cited by 2,044

Show all 41 references

Research works printed but not linked: 14

10.1161/atvb.21.11.1712 · DOI
10.1161/circ.89.6.8205659 · DOI
10.1161/circ.101.16.1899 · DOI
10.1161/circ.101.9.948 · DOI
10.1161/circ.104.22.2673 · DOI
10.1161/circ.104.4.376 · DOI
10.1161/circ.95.5.1126 · DOI
10.1161/circ.97.12.1129 · DOI
10.1161/circ.105.8.933 · DOI
10.1161/atvb.22.2.300 · DOI
10.1161/atvb.20.1.61 · DOI
10.1161/atvb.21.1.122 · DOI
10.1161/circ.95.1.76 · DOI
10.1161/circ.100.3.230 · DOI

Sorted by citations

Items 101–177 of 177

Intravenous administration of pravastatin immediately after middle cerebral artery occlusion reduces cerebral oedema in spontaneously hypertensive rats
Mariucci, G., Taha, E., Tantucci, M., Spaccatini, C., Tozzi, A., & Ambrosini, M. V. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.04.002 · Cited by 15
Systematic review and meta-analysis of perioperative and long-term outcomes in patients receiving statin therapy before carotid endarterectomy
Ironside, N. T., Brenner, D., Heyer, E. J., Chen, C., Robison, T. R., Christophe, B. R., & Connolly, E. S. (2018) · Acta Neurochirurgica · doi:10.1007/s00701-018-3618-5 · Cited by 15
High versus low dose statin therapy in Indian patients with acute ST-segment elevation myocardial infarction undergoing thrombolysis
Priti, K., Agrawal, A., & Ranwa, B. L. (2017) · Indian Heart Journal · doi:10.1016/j.ihj.2017.05.026 · Cited by 15
Statins in the prevention of perioperative cardiovascular complications
Schouten, O., & Poldermans, D. (2005) · Current Opinion in Anaesthesiology · doi:10.1097/00001503-200502000-00009 · Cited by 15
Antifungal Activity of Fibrate-Based Compounds and Substituted Pyrroles That Inhibit the Enzyme 3-Hydroxy-methyl-glutaryl-CoA Reductase of Candida glabrata (CgHMGR), Thus Decreasing Yeast Viability and Ergosterol Synthesis
Madrigal-Aguilar, D. A., González-Silva, A., Rosales-Acosta, B., Bautista-Crescencio, C., Ortiz-Álvarez, J., Escalante, C. H., Sánchez-Navarrete, J., Hernández-Rodríguez, C., Chamorro, G., Tamariz, J., et al. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.01642-21 · Cited by 15
Effect of Danlou Tablet (丹蒌片) on peri-procedural myocardial injury among patients undergoing percutaneous coronary intervention for non-ST elevation acute coronary syndrome: A study protocol of a multicenter, randomized, controlled trial
Wang, L., Mao, S., Qi, J., Ren, Y., Guo, X., Chen, K., & Zhang, M. (2015) · Chinese Journal of Integrative Medicine · doi:10.1007/s11655-015-2284-1 · Cited by 14
Beneficial Effects of Pitavastatin, a 3-Hydroxy-3-Methylglutaryl Coenzyme a Reductase Inhibitor, on Cardiac Function in Ischemic and Nonischemic Heart Failure
Aoyagi, T., Nakamura, F., Tomaru, T., & Toyo‐oka, T. (2008) · International Heart Journal · doi:10.1536/ihj.49.49 · Cited by 14
Protective effects of simvastatin on coronary artery function in swine with acute infection
Liuba, P., Pesonen, E. J., Forslid, A., Paakkari, I., Kornerup-Hansen, A., Kovanen, P. T., Pentikäinen, M. O., Persson, K., & Østergård, G. (2005) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2005.08.017 · Cited by 14
Simvastatin suppresses expression of angiogenic factors in the retinas of rats with streptozotocin-induced diabetes
Lee, S. G., Kim, J. L., Lee, H. K., Ryu, G. W., Hur, D. Y., Yun, I. H., Yang, J. W., & Kim, H. W. (2010) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-010-1496-5 · Cited by 14
Preprocedural statin therapy, inflammation, and myocardial injury in low‐risk stable coronary artery disease patients submitted to coronary stent implantation
Greque, G. V., Junior, C. V. S., Strunz, C. M. C., Soeiro, A. M., dos Santos, M. A., Pivatelli, F. C., Jl, J., Pesaro, A. E. P., Nicolau, J. C., & Filho, R. K. (2013) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.24937 · Cited by 14
Effects of short-term anti-inflammatory therapy on endothelial function in patients with non-ST-segment elevation acute coronary syndrome
Chyrchel, M., Dudek, D., Rzeszutko, Ł., Dziewierz, A., Chyrchel, B., Rakowski, T., & Dubiel, J. S. (2010) · Cardiovascular revascularization medicine · doi:10.1016/j.carrev.2009.11.001 · Cited by 13
Low-density lipoprotein reduction by simvastatin is accompanied by angiotensin II type 1 receptor downregulation, reduced oxidative stress, and improved endothelial function in patients with stable coronary artery disease
Kiliszek, M., Ma̧czewski, M., Styczyński, G., Duda, M. K., Opolski, G., & Berȩsewicz, A. (2007) · Coronary Artery Disease · doi:10.1097/mca.0b013e32802c7cb0 · Cited by 13
Efficacy comparison of atorvastatin versus rosuvastatin on blood lipid and microinflammatory state in maintenance hemodialysis patients
Tian, J., Hou, X., Hu, L., Chen, T., Wu, K., Cai, C., & Bai, X. (2016) · Renal Failure · doi:10.1080/0886022x.2016.1256309 · Cited by 13
Early statin therapy in patients with acute coronary syndrome.
Liberopoulos, E. N., Daskalopoulou, S. S., & Mikhailidis, D. P. (2005) · PubMed · Cited by 13
Acute Effects of Statins
Laufs, U., & Adam, O. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.08.063 · Cited by 14
Impact of High-Dose Statin Pretreatment in Patients with Stable Angina during Off-Pump Coronary Artery Bypass
Youn, Y., Park, S.-Y., Hwang, Y., Joo, H.-C., & Yoo, K. (2011) · The Korean Journal of Thoracic and Cardiovascular Surgery · doi:10.5090/kjtcs.2011.44.3.208 · Cited by 12
Impact on Renal Function of Rosuvastatin Preload Prior to Elective Percutaneous Coronary Intervention in Chronic Statin Users
Oliveira, M., Martins, K. B. A., Costa, J. R., Abizaid, A., Stadler, J. R., Mattos, L. A., Chamié, D., Siqueira, D. A., da Costa, R. A., Staico, R., et al. (2012) · Revista Brasileira de Cardiologia Invasiva (English Edition) · doi:10.1016/s2214-1235(15)30069-7 · Cited by 12
HMG-coA reductase inhibitors: lipid-lowering and beyond
Lutgens, E., & Daemen, M. J. A. P. (2004) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2004.09.005 · Cited by 12
A systematic review and meta-analysis of the effect of high-intensity statin on coronary microvascular dysfunction
Huang, B., Han, X., Pan, Y., & Chen, D. (2023) · BMC Cardiovascular Disorders · doi:10.1186/s12872-023-03402-9 · Cited by 13
Intensive statin therapy for Chinese patients with coronary artery disease undergoing percutaneous coronary intervention (ISCAP study)
Liu, P., Jiang, J., Li, J., Hong, T., Zhang, Y., Yu, R., Jia, J., & Huo, Y. (2011) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.23171 · Cited by 9
Effects of atorvastatin loading prior to primary percutaneous coronary intervention on endothelial function and inflammatory factors in patients with ST-segment elevation myocardial infarction
Yong, H., Wang, X., MI, L., Guo, L., Gao, W., Zhang, Y., & Cui, M. (2013) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2013.1432 · Cited by 9
Statin loading for acute coronary syndromes
Nusca, A., Melfi, R., Patti, G., & Sciascio, G. D. (2010) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e32833987ca · Cited by 9
Impact of Atorvastatin Treatment in First‐Degree Relatives of Patients With Premature Coronary Artery Disease With Endothelial Dysfunction: A Double‐Blind, Randomized, Placebo‐Controlled Crossover Trial
Hong, S., Chang, H., Park, S., Kang, D. R., Shin, S., Cho, I., Shim, C. Y., Hong, G., Ha, J., & Chung, N. (2013) · Clinical Cardiology · doi:10.1002/clc.22152 · Cited by 8
Impact on Renal Function of Rosuvastatin Preload Prior to Elective Percutaneous Coronary Intervention in Chronic Statin Users
Oliveira, M., Martins, K. B. A., Costa, J. R., Abizaid, A., Stadler, J. R., Mattos, L. A., Chamié, D., Siqueira, D., da Costa, R. A., Staico, R., et al. (2012) · Revista Brasileira de Cardiologia Invasiva · doi:10.1016/s0104-1843(12)50051-2 · Cited by 8
Effects of High-dose Atorvastatin Pretreatment in Patients with ST-segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Cardiac Magnetic Resonance Study
Kim, E. K., Hahn, J., Song, Y. B., Chang, S.-A., Choi, J., Choi, S., Lee, S., Choe, Y. H., Lee, S. H., & Gwon, H. (2015) · Journal of Korean Medical Science · doi:10.3346/jkms.2015.30.4.435 · Cited by 8
Randomized Trial of Anti-inflammatory Medications and Coronary Endothelial Dysfunction in Patients With Stable Coronary Disease
Hays, A. G., Schär, M., Bonanno, G., Lai, S., Meyer, J., Afework, Y., Steinberg, A. M., Stradley, S., Gerstenblith, G., & Weiss, R. G. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.728654 · Cited by 6
Relationship between low‐density lipoprotein levels on admission and 1‐year outcome in patients with acute ST‐segment‐elevation myocardial infarction
Sun, Y., Li, Y., Jiang, D., Zhang, B., Gao, Y., Zhang, Z., & Qi, G. (2012) · The Kaohsiung Journal of Medical Sciences · doi:10.1016/j.kjms.2012.08.036 · Cited by 6
Protective effect of fluvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on copper-induced hydroxyl radical generation in the rat heart
Obata, T. (2006) · Toxicology · doi:10.1016/j.tox.2006.03.006 · Cited by 6
Short-term high-dose atorvastatin for periprocedural myocardial infarction prevention in patients with renal dysfunction
Patti, G. (2011) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0b013e3283454faa · Cited by 6
Review: Percutaneous coronary interventions and statins therapy
Nusca, A., Melfi, R., & Sciascio, G. D. (2008) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944708089983 · Cited by 5
Rosuvastatin for Reduction of Myocardial Damage during Coronary Angioplasty - the Remedy Trial
Briguori, C., Madonna, R., Zimarino, M., Calabrò, P., Quintavalle, C., Salomone, M., Condorelli, G., & Caterina, R. D. (2016) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-016-6672-3 · Cited by 5
Impact of statin usage patterns on outcomes after percutaneous coronary intervention in acute myocardial infarction: Korea Working Group on Myocardial Infarction registry (KorMI) study.
Lee, C.-H., Lee, S.-H., Park, J., Kim, Y., Kim, K., Chae, S.-C., Kim, H.-S., Choi, D., Cho, M., Rha, S., et al. (2014) · Europe PMC (PubMed Central) · doi:10.3969/j.issn.1671-5411.2014.02.010 · Cited by 5
The ARMYDA trials (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) at Campus Bio‐Medico University: rationale, results and future horizons
Sciascio, G. D. (2007) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2007.00539.x · Cited by 5
Effect of Statins Therapy Prior to Percutaneous Coronary Intervention
Luo, J., Xu, L., Yu, T., & Li, J. (2012) · Journal of Interventional Cardiology · doi:10.1111/j.1540-8183.2011.00709.x · Cited by 4
Very rapid effect of pitavastatin on microvascular function in comparison to rosuvastatin: reactive hyperemia peripheral arterial tonometric study
Fukuda, Kono, Shimada, Nakanishi, ○., Otsuka, Kubo, Jissho, Taguchi, H., Yoshikawa, & Yoshiyama (2013) · Drug Design Development and Therapy · doi:10.2147/dddt.s44099 · Cited by 4
Atorvastatin at Reperfusion Reduces Myocardial Infarct Size in Mice by Activating eNOS in Bone Marrow-Derived Cells
Tian, Y., Linden, J. M., French, B. A., & Yang, Z. (2014) · PLoS ONE · doi:10.1371/journal.pone.0114375 · Cited by 4
Statins and hypertension
Cífková, R., & Nilsson, P. M. (2009) · Journal of Hypertension · doi:10.1097/hjh.0b013e3283223ebb · Cited by 4
Antiplatelet and Lipid-lowering Drugs in Hypertension
Cífková, R. (2014) · European Cardiology Review · doi:10.15420/ecr.2014.9.1.16 · Cited by 4
Single high dose atorvastatin does not ameliorate endothelial function and large arterial stiffness in dyslipidemic patients without atherosclerosis.
Tulmaç, M., Şimşek, Tireli, E., Şahin, Ö., Yıldırım, N., Mt, D., & Ebinç, H. (2012) · PubMed · Cited by 4
Ischemic Heart Disease
Chrysant, G. S., & Oparil, S. (2005) · Elsevier eBooks · doi:10.1016/b978-0-7216-0258-5.50144-7 · Cited by 4
Atorvastatin for reduction of myocardial damage during angioplasty trials
Nusca, A., Melfi, R., Patti, G., & Sciascio, G. D. (2010) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0b013e32833a0a5d · Cited by 4
Impacto na função renal de uma dose de reforço de rosuvastatina prévia a intervenção coronária percutânea eletiva nos pacientes em uso crônico de estatina
Oliveira, M., Martins, K. B. A., Costa, J. R., Abizaid, A., Stadler, J. R., Mattos, L. A., Chamié, D., Siqueira, D. A., da Costa, R. A., Staico, R., et al. (2012) · Revista Brasileira de Cardiologia Invasiva · doi:10.1590/s2179-83972012000300014 · Cited by 3
Effects of rosuvastatin correlated with the down-regulation of CYP4A1 in spontaneously hypertensive rats
Li, D., Xu, H.-W., Yang, G., Yang, J., He, F., & Tang, J.-Y. (2015) · Microvascular Research · doi:10.1016/j.mvr.2015.01.005 · Cited by 3
Overview of Oxidative Stress and Cardiovascular Disease
Elahi, M. M., Chuang, A., & Matata, B. M. (2014) · Springer eBooks · doi:10.1007/978-3-642-30018-9_42 · Cited by 3
Dyslipidemia and Endothelial Dysfunction: Pathophysiology and Therapy
Anderson, T. J., & Charbonneau, F. (2007) · doi:10.1002/9780470988473.ch17 · Cited by 3
Intensive statin therapy in acute coronary syndromes: clinical benefits and vascular biology
Ray, K. K., & Cannon, C. P. (2005) · Current Opinion in Internal Medicine · doi:10.1097/00132980-200502000-00006 · Cited by 2
Impact of prior statin use on percutaneous coronary intervention outcomes in acute coronary syndrome
Cantarelli, M. J. D. C., Gioppato, S., Castello, H. J., Gonçalves, R., Ribeiro, E. K. P., Guimarães, J. B. D. F., Navarro, E. C., Maksud, D., & Vardi, J. C. F. (2015) · Revista Brasileira de Cardiologia Invasiva (English Edition) · doi:10.1016/j.rbciev.2015.12.008 · Cited by 1
Lipids, Atherogenic Dyslipidemia, and Therapy
Levine, T. B., & Levine, A. B. (2012) · Wiley eBooks · doi:10.1002/9781118480045.ch13 · Cited by 1
Prevention of Perioperative Cardiovascular Complications in non-cardiac Surgery: the Future Role of Statins
Schouten, O., Bax, J. J., & Poldermans, D. (2005) · Future Cardiology · doi:10.2217/14796678.1.6.701 · Cited by 1
Plaque passivation: role of statins in acute coronary syndromes.
Singh, S., & Bahl, V. K. (2003) · PubMed · Cited by 1
Thromboembolic Events in the Perioperative Period
van Lier, F. (2011) · EUR Research Repository (Erasmus University Rotterdam)
Treatment of Endothelial Dysfunction and Atherosclerosis by Cholesterol Lowering
Aikawa, M., & Libby, P. (2007) · doi:10.1002/9780470988473.ch21
Lipids, inflammation, and the Renin-Angiotensin System
van der Harst, P. (2006)
Estudo da reatividade vascular em ratos submetidos à isquemia e reperfusão instestinal: mecanismos envolvidos e papel protetor da sinvastatina.
Peres, E. C. (2012) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.42.2012.tde-29012013-104107
Statins and perioperative myocardial infarction. Mechanisms of action
Levin, A. I., & Coetzee, A. (2007) · Southern African Journal of Anaesthesia and Analgesia · doi:10.1080/22201173.2007.10872496
Clinical benefits of statin pretreatment in patients undergoing coronary revascularization
Melfi, R., Nusca, A., Sciascio, G. D., & Patti, G. (2010) · Clinical Lipidology · doi:10.2217/clp.10.10
Die Bedeutung der monozytären Rac1 GTPase und der glattmuskulären Integrin-Linked Kinase für die Pathogenese der Atherosklerose
Medizin, I., & Böhm, M. (2007)
Impacto do uso prévio de estatinas nos resultados da intervenção coronária percutânea na síndrome coronariana aguda
Cantarelli, M. J. D. C., Gioppato, S., Castello, H. J., Gonçalves, R., Ribeiro, E. K. P., Guimarães, J. B. D. F., Navarro, E. C., Maksud, D., & Vardi, J. C. F. (2015) · Revista Brasileira de Cardiologia Invasiva · doi:10.1016/j.rbci.2015.12.008
Einfluss des AT 1 -Rezeptorantagonismus auf die Hypercholesterinämie-induzierte endotheliale Dysfunktion
Medizin, I., & Böhm, M. (2005)
LDL-lowering Independent Effects of Early Pre-treatment with High-dose Statins in Patients Undergoing Percutaneous Coronary Interventions CARDIOVASCULAR RISK PREVENTION | REVIEW
Sciascio, G. D., Nusca, A., Melfi, R., & Patti, G. (2011)
Statyny a nadciśnienie tętnicze
Cífková, R., & Nilsson, P. M. (2008) · Via Medica Journals
In addition to their lipid-lowering effects, statins are now thought to have many other beneficial mechanisms of action. The Effects of Statins on Endothelium, Inflammation and Cardioprotection
Elrod, J. W., & Lefer, D. J. (2005)
Beyond the Lipid-lowering Effects of Statins: Renal Effects
Kaya, Y., Kaya, A., & Bekataş, O. (2017) · Koşuyolu Heart Journal · doi:10.5578/khj.10606
Association of hyperlipidemia and statin use with severity of COVID-19Preprint
Tan, W. Y., Young, B. E., Lye, D. C., Chew, D. E. K., & Dalan, R. (2020) · doi:10.21203/rs.3.rs-40008/v1
Promising Effects of Atorvastatin on Outcomes of Patients with Severe COVID-19, A Retrospective Cohort StudyPreprint
Aghajani, M. H., Moradi, O., Tehrani, H. A., Amini, H., Pourheidar, E., Hatami, F., Rabiei, M. M., & Sistanizad, M. (2021) · doi:10.22541/au.161346533.33804535/v1
Effect of Selective/Non-selective COX Inhibition on Rosuvastatin-Mediated Protection from Ischemia-reperfusion Induced Endothelial Dysfunction in the Human Forearm Vasculature
Kwong, W. (2011) · TSpace (University of Toronto)
Antifungal activity of fibrate-based compounds and substituted pyrroles inhibiting the enzyme 3-hydroxy-methyl-glutaryl-CoA reductase of Candida glabrata (CgHMGR), and decreasing yeast viability and ergosterol synthesisPreprint
Madrigal-Aguilar, D. A., González-Silva, A., Rosales-Acosta, B., Bautista-Crescencio, C., Ortiz-Álvarez, J., Escalante, C. H., Sánchez-Navarrete, J., Hernández-Rodríguez, C., Chamorro, G., Tamariz, J., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.09.14.460412
Special Patient Populations
Schwartz, G. G. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00036-4
Effect of Pravastatin on Levels of Malondealdehyde (MDA) And Endothelin-1 (ET-1) Preeclampsia Model Rats
Andriyanti, A., Restiningsih, R., Rahardjo, B., Nooryanto, M., Winarsih, S., Permatasari, N., & Indriani, A. (2023) · Malaysian Journal of Medicine and Health Sciences · doi:10.47836/mjmhs.19.1.13
Statins Versus PDE-5 Inhibitors: A Comparative Study in Controlled Diabetes Mellitus Patients with Erectile Dysfunction
Chakaravarthy, P., Vadlamani, B., Kant, R., Chauhan, U., Kapre, M., & Mittal, A. (2023) · Journal of Cardio-diabetes and metabolic disorders · doi:10.4103/jcdm.jcdm_5_22
Special Patient Populations
Schwartz, G. G., & Do, R. Q. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-28786-9.00039-6
Endothelial dysfunction in systemic hypertension
Yu, C., Sharma, A., Trane, A., & Bernatchez, P. N. (2010) · Springer eBooks · doi:10.1007/978-3-0346-0168-9_6
Additional file 1 of A systematic review and meta-analysis of the effect of high-intensity statin on coronary microvascular dysfunction
Huang, B., Han, X., Pan, Y., & Chen, D. D. (2023) · Figshare · doi:10.6084/m9.figshare.23740625
Predictive ability of microvascular resistance reserve for periprocedural myocardial injury in patients with stable coronary artery disease undergoing percutaneous coronary intervention
Shigehara, M., Ikenaga, H., Yoshitomi, Y., Kobatake, H., Kuraishi, A., Osawa, A., Nakano, T., Morita, Y., Higashihara, T., Watanabe, N., et al. (2025) · Heart and Vessels · doi:10.1007/s00380-025-02646-z
Плейотропні ефекти статинів: більше ніж просто зниження холестерину
Kanishcheva, O., Tselik, N. E., Lebedynska, M. M., & Shop, I. V. (2026) · Ukrainian Journal of Cardiology · doi:10.31928/2664-4479-2026.3.4656
Prevalence of Hypertension and Associated Factors in Patients with Type 2 Diabetes in Tigray Region, Northern Ethiopia: A Cross-Sectional Study
Berhe, K. K., & Gebremichael, G. B. (2025) · ASRIC Journal on Health Sciences · doi:10.68327/tezs3786
Oxidative stress and atherosclerosis: from LDL oxidation and foam cell formation to plaque instability – three decades of evidence and remaining therapeutic challenges
Ji, L., & Du, H. (2026) · Frontiers in Physiology · doi:10.3389/fphys.2026.1968314

Authors: Wassmann, S., Faul, A., Hennen, B., Scheller, B., Böhm, M., & Nickenig, G.
Affiliations: Universitätsklinikum des Saarlandes (DE)
From Medizinische Klinik und Poliklinik, Innere Medizin III, Universitätskliniken des Saarlandes, Homburg/Saar, Germany.
ORCID: Wassmann, Sven
Scheller, Bruno
Nickenig, Georg
Venue: Circulation Research
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2003-10-31
Volume: 93
Issue: 9
Pages: e98-103
ISSN: 0009-7330 (ISSN-L)
1524-4571
DOI: 10.1161/01.res.0000099503.13312.7b
OpenAlex: W2166462038
Cited by: 177
References: 41
Citations by year: 2026: 2 · 2025: 2 · 2023: 5 · 2022: 1 · 2021: 6 · 2020: 3 · 2019: 1 · 2018: 3 · 2017: 2 · 2016: 3 · 2015: 8 · 2014: 8 · 2013: 5 · 2012: 11
FWCI: 16.72
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Circulation Research (publishedVersion)
PubMed (publishedVersion)
Funders: Bristol-Myers Squibb
Deutsche Forschungsgemeinschaft
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Health Sciences › Medicine › Physiology (medical) › Nitric Oxide and Endothelin Effects
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
Keywords: pravastatin, statins, coronary endothelial function, endothelial dysfunction, acetylcholine-induced vasoconstriction, nitroglycerin, coronary blood flow reserve, adenosine, stable angina, hypercholesterolemia, coronary vasculature, lipid-lowering therapy
MeSH terms: Aged, Angina Pectoris, Blood Flow Velocity, Blood Pressure, C-Reactive Protein, Coronary Circulation, Coronary Vessels, Double-Blind Method, Endothelium, Vascular, Female, Heart Rate, Humans, Hydroxymethylglutaryl CoA Reductases, Lipids, Male, Middle Aged, Prospective Studies, Time Factors, Vascular Patency, Vasodilation, Vasodilator Agents, Coronary Angiography, Pravastatin, Hydroxymethylglutaryl-CoA Reductase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Rapid Effect of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibition on Coronary Endothelial Function

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks